Nicholas J. Kramer

Senior Research Scientist II at Sterling Pharma Solutions

Nicholas J. Kramer, Ph.D. has experience in process development of small molecule APIs at various scales, from milligram to multi-kilogram scale. Currently a Senior Research Scientist at Sterling Pharma Solutions, involved in R&D development into late-stage cGMP manufacturing. Previous roles include being a Research Scientist at the same company, a Postdoctoral Research Associate at UNC Eshelman School of Pharmacy, an Adjunct Professor of Chemistry at Thomas University, a Co-Op at GSK, and a Summer Intern at Vassar College. Holds a Ph.D. in Chemistry with a focus on Organic Chemistry from Florida State University, and a Bachelor's degree in Biochemistry from Ramapo College of New Jersey.

Location

Raleigh, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Sterling Pharma Solutions

1 followers

Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities


Industries

Employees

1,001-5,000

Links